糖复合物
免疫原性
结合
沙门氏菌
抗原
化学
福氏志贺氏菌
糖基化
微生物学
组合化学
大肠杆菌
生物化学
生物
细菌
免疫学
基因
数学分析
遗传学
数学
作者
Rebecca Nappini,Renzo Alfini,Salvatore Durante,Laura Salvini,Maria Michelina Raso,Elena Palmieri,Roberta Di Benedetto,Martina Carducci,Omar Rossi,Paola Cescutti,Francesca Micoli,Carlo Giannelli
出处
期刊:Vaccines
[Multidisciplinary Digital Publishing Institute]
日期:2024-06-24
卷期号:12 (7): 707-707
标识
DOI:10.3390/vaccines12070707
摘要
Glycoconjugation is a well-established technology for vaccine development: linkage of the polysaccharide (PS) antigen to an appropriate carrier protein overcomes the limitations of PS T-independent antigens, making them effective in infants and providing immunological memory. Glycoconjugate vaccines have been successful in reducing the burden of different diseases globally. However, many pathogens still require a vaccine, and many of them display a variety of glycans on their surface that have been proposed as key antigens for the development of high-valency glycoconjugate vaccines. CDAP chemistry represents a generic conjugation strategy that is easily applied to PS with different structures. This chemistry utilizes common groups to a large range of PS and proteins, e.g., hydroxyl groups on the PS and amino groups on the protein. Here, new fast analytical tools to study CDAP reaction have been developed, and reaction conditions for PS activation and conjugation have been extensively investigated. Mathematical models have been built to identify reaction conditions to generate conjugates with wanted characteristics and successfully applied to a large number of bacterial PSs from different pathogens, e.g., Klebsiella pneumoniae, Salmonella Paratyphi A, Salmonella Enteritidis, Salmonella Typhimurium, Shighella sonnei and Shigella flexneri. Furthermore, using Salmonella Paratyphi A O-antigen and CRM197 as models, a design of experiment approach has been used to study the impact of conjugation conditions and conjugate features on immunogenicity in rabbits. The approach used can be rapidly extended to other PSs and accelerate the development of high-valency glycoconjugate vaccines.
科研通智能强力驱动
Strongly Powered by AbleSci AI